Lupin said it has acquired diabetes brands Ondero (linagliptin) and Ondero Met (linagliptin and metformin) from Boehringer Ingelheim including the trademark rights associated with these brands for 26 million euros (Rs 235 crore) in an all cash deal.
Lupin didn’t disclose the latest sales of Ondero and Ondero Met, but said the acquisition is expected to be value accretion to Lupin diabetic portfolio.
Lupin has been marketing Ondero and Ondero Met since 2015 in the Indian market as part of a co-marketing agreement with Boehringer Ingelheim India.
In India, an estimated 77 million people above the age of 18 years have Type-2 Diabetes, while nearly 25 million are pre-diabetic, at higher risk of developing diabetes in the future.
“With the acquisition of Ondero and Ondero Met, we continue to offer a wide portfolio of products to enable access to medication for patients, and further consolidate our position as a market leader in the anti-diabetes segment,” said Nilesh Gupta, MD of Lupin.
Source: Economic Times